Copyright
©The Author(s) 2020.
World J Clin Cases. Feb 6, 2020; 8(3): 487-503
Published online Feb 6, 2020. doi: 10.12998/wjcc.v8.i3.487
Published online Feb 6, 2020. doi: 10.12998/wjcc.v8.i3.487
Figure 1 Five-year recurrence-free survival and overall survival.
A: Five-year recurrence-free survival and overall survival at a median follow-up of 54 mo with 3-year vs 1-year imatinib adjuvant treatment in patients with resected gastrointestinal stromal tumors estimated to be at high risk of recurrence[39]. B: Five-year recurrence-free survival and overall survival at a median follow-up of 90 mo with 3-year vs 1-year imatinib adjuvant treatment in patients with resected gastrointestinal stromal tumors estimated to be at high risk of recurrence[40]. OS: Overall survival; RFS: Recurrence-free survival.
- Citation: Rare Tumors GI Group, Farhat F, Farsi AA, Mohieldin A, Bahrani BA, Sbaity E, Jaffar H, Kattan J, Rasul K, Saad K, Assi T, Morsi WE, Abood RA. Comprehensive review into the challenges of gastrointestinal tumors in the Gulf and Levant countries. World J Clin Cases 2020; 8(3): 487-503
- URL: https://www.wjgnet.com/2307-8960/full/v8/i3/487.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v8.i3.487